TZ 101

Drug Profile

TZ 101

Alternative Names: ASC-101; Ftv1+Gdp-Fucose; GDP-fucose protein O-fucosyltransferase 1 - Targazyme; Peptide-O-fucosyltransferase - Targazyme; TZ101

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator America Stem Cell
  • Developer America Stem Cell; Indiana University School of Medicine; Oregon Health & Science University; Targazyme; University of California, San Diego; University of Texas M. D. Anderson Cancer Center; Wake Forest University School of Medicine
  • Class Fucosyltransferases; Hexosyltransferases
  • Mechanism of Action Fucosyltransferase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies; Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Graft-versus-host disease; Haematological malignancies
  • Preclinical Leukaemia; Multiple myeloma
  • No development reported Diabetic retinopathy; Multiple sclerosis; Muscle injury; Myelodysplastic syndromes; Myocardial infarction; Peripheral ischaemia; Stomatitis
  • Discontinued Autoimmune disorders; Bone metastases; Stroke

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Muscle injury in USA (IV)
  • 25 Apr 2017 M.D. Anderson Cancer Center completes a phase I/II trial in Haematological malignancies in USA (Parenteral) (NCT01471067)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top